{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:15:38Z","timestamp":1786965338534,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s40265-020-01323-x","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T11:03:51Z","timestamp":1592564631000},"page":"995-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With\/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-3689","authenticated-orcid":false,"given":"Jos\u00e9 C.","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Miede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Godoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The RE-DUAL PCI Steering Committee and Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"issue":"2","key":"1323_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"GYH Lip","year":"2019","unstructured":"Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21(2):192\u20133.","journal-title":"Europace."},{"issue":"10","key":"1323_CR2","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123\u201355.","journal-title":"Circulation."},{"issue":"26","key":"1323_CR3","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa012877","volume":"346","author":"KC Lai","year":"2002","unstructured":"Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033\u20138.","journal-title":"N Engl J Med."},{"issue":"1","key":"1323_CR4","doi-asserted-by":"publisher","first-page":"e000248","DOI":"10.1136\/openhrt-2015-000248","volume":"2","author":"RN Cardoso","year":"2015","unstructured":"Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart. 2015;2(1):e000248.","journal-title":"Open Heart."},{"issue":"2","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","volume":"56","author":"JS Hulot","year":"2010","unstructured":"Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134\u201343.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"1323_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1161\/CIRCULATIONAHA.111.032912","volume":"125","author":"SG Goodman","year":"2012","unstructured":"Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125(8):978\u201386.","journal-title":"Circulation."},{"issue":"4","key":"1323_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ahj.2015.05.017","volume":"170","author":"JC Nicolau","year":"2015","unstructured":"Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalan R, et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J. 2015;170(4):683\u201394.e3.","journal-title":"Am Heart J."},{"issue":"11","key":"1323_CR8","doi-asserted-by":"publisher","first-page":"e002245","DOI":"10.1161\/JAHA.115.002245","volume":"4","author":"MW Sherwood","year":"2015","unstructured":"Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11):e002245.","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"1323_CR9","doi-asserted-by":"publisher","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","volume":"10","author":"NH Shah","year":"2015","unstructured":"Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653.","journal-title":"PLoS One."},{"issue":"20","key":"1323_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909\u201317.","journal-title":"N Engl J Med."},{"issue":"6","key":"1323_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1053\/j.gastro.2016.08.054","volume":"151","author":"WA Ray","year":"2016","unstructured":"Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of proton pump inhibitors with reduced risk of warfarin-related serious upper gastrointestinal bleeding. Gastroenterology. 2016;151(6):1105\u201312.e10.","journal-title":"Gastroenterology."},{"issue":"21","key":"1323_CR12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320(21):2221\u201330.","journal-title":"JAMA."},{"issue":"3","key":"1323_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2015.05.002","volume":"149","author":"EW Chan","year":"2015","unstructured":"Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149(3):586\u201395.e3.","journal-title":"Gastroenterology."},{"issue":"5","key":"1323_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1756283X17694807","volume":"10","author":"R Sharma","year":"2017","unstructured":"Sharma R, Roy A, Ramos C, Rosenberg R, Garcia-Carrasquillo R, Lebwohl B. Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation. Therap Adv Gastroenterol. 2017;10(5):387\u201396.","journal-title":"Therap Adv Gastroenterol."},{"key":"1323_CR15","unstructured":"Center for Drug Evaluation and Research. Clinical pharmacology review NDA 22-512, dabigatran. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf. Accessed 19 Mar 2019."},{"issue":"16","key":"1323_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513\u201324.","journal-title":"N Engl J Med."},{"issue":"10","key":"1323_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"CP Cannon","year":"2016","unstructured":"Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016;39(10):555\u201364.","journal-title":"Clin Cardiol."},{"issue":"19","key":"1323_CR18","doi-asserted-by":"publisher","first-page":"1726-35a","DOI":"10.1093\/eurheartj\/ehy162","volume":"39","author":"HB Golwala","year":"2018","unstructured":"Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018;39(19):1726-35a.","journal-title":"Eur Heart J."},{"issue":"8","key":"1323_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","volume":"4","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Hong H, Harskamp RE, Bhatt DL, Mehran R, Cannon CP, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. JAMA Cardiol. 2019;4(8):747\u201355.","journal-title":"JAMA Cardiol."},{"issue":"3","key":"1323_CR20","doi-asserted-by":"publisher","first-page":"e9638","DOI":"10.1097\/MD.0000000000009638","volume":"97","author":"W Hu","year":"2018","unstructured":"Hu W, Tong J, Kuang X, Chen W, Liu Z. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis. Medicine (Baltimore). 2018;97(3):e9638.","journal-title":"Medicine (Baltimore)."},{"issue":"9","key":"1323_CR21","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.amjmed.2016.03.042","volume":"129","author":"M Vaduganathan","year":"2016","unstructured":"Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016;129(9):1002\u20135.","journal-title":"Am J Med."},{"issue":"14","key":"1323_CR22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jacc.2015.12.068","volume":"67","author":"M Vaduganathan","year":"2016","unstructured":"Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, et al. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol. 2016;67(14):1661\u201371.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"1323_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682\u201391.e2.","journal-title":"Gastroenterology."},{"issue":"2","key":"1323_CR24","doi-asserted-by":"publisher","first-page":"403-12.e5","DOI":"10.1053\/j.gastro.2019.04.041","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403-12.e5.","journal-title":"Gastroenterology."},{"issue":"12","key":"1323_CR25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med."},{"issue":"2","key":"1323_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH13-02-0150","volume":"110","author":"J Desai","year":"2013","unstructured":"Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants: defining the issues and the management strategies. Thromb Haemost. 2013;110(2):205\u201312.","journal-title":"Thromb Haemost."},{"issue":"16","key":"1323_CR27","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J."},{"issue":"5","key":"1323_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cgh.2016.12.033","volume":"15","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Bhatt DL. Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem. Clin Gastroenterol Hepatol. 2017;15(5):691\u20133.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"21","key":"1323_CR29","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363\u201372.","journal-title":"Circulation."},{"issue":"5","key":"1323_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/ajg.2017.39","volume":"112","author":"DJ Cangemi","year":"2017","unstructured":"Cangemi DJ, Krill T, Weideman R, Cipher DJ, Spechler SJ, Feagins LA. A comparison of the rate of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants or warfarin. Am J Gastroenterol. 2017;112(5):734\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"23","key":"1323_CR31","doi-asserted-by":"publisher","first-page":"1708-13, 13a\u201313","DOI":"10.1093\/eurheartj\/eht042","volume":"34","author":"S Agewall","year":"2013","unstructured":"Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708-13, 13a\u201313b.","journal-title":"Eur Heart J."},{"issue":"6","key":"1323_CR32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.joa.2017.07.013","volume":"33","author":"T Kuwayama","year":"2017","unstructured":"Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A, et al. Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm. 2017;33(6):619\u201323.","journal-title":"J Arrhythm."},{"issue":"19","key":"1323_CR33","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","volume":"40","author":"J Oldgren","year":"2019","unstructured":"Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553\u201362.","journal-title":"Eur Heart J."},{"issue":"1","key":"1323_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12872-016-0453-6","volume":"17","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Teeluck AR, Bhurtu A, Huang WQ. Is the concomitant use of clopidogrel and proton pump inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty? A systematic review and meta-analysis of recently published studies (2012\u20132016). BMC Cardiovasc Disord. 2017;17(1):3.","journal-title":"BMC Cardiovasc Disord."},{"issue":"9694","key":"1323_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989\u201397.","journal-title":"Lancet."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01323-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01323-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01323-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T23:29:55Z","timestamp":1624058995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01323-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01323-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]},"assertion":[{"value":"19 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jos\u00e9 C. Nicolau has received research grants from CSL Behring, Sanofi, AstraZeneca, Bristol-Myers Squibb, Viforpharma, Dalcorpharma, Janssen, and Novartis; has served as a consultant\/advisory board member for Bayer, Merck, Novartis, Sanofi, Servier, Amgen, and AstraZeneca; and a steering committee member for Eisai, Boehringer Ingelheim, AstraZeneca, Sanofi, CSL Behring, Viforpharma, and Dalcorpharma. Deepak L. Bhatt discloses the following relationships: Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor-in-Chief, <i>Journal of Invasive Cardiology<\/i>), <i>Journal of the American College of Cardiology<\/i> (Guest Editor; Associate Editor), Medtelligence\/ReachMD (CME steering committees), Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today\u2019s Intervention), Society of Cardiovascular Patient Care (Secretary\/Treasurer), WebMD (CME steering committees); other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, <i>Cardiovascular Intervention: A Companion to Braunwald\u2019s Heart Disease<\/i>); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, PLx Pharma, Takeda. Stefan H. Hohnloser has received personal fees from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer, SJM, and ZOLL. Takeshi Kimura has received grants from Boehringer Ingelheim. Gregory Y.H. Lip has served as a consultant for Bayer\/Janssen, Bristol-Meyers Squibb\/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi Sankyo. He has been a speaker for Bayer, Bristol-Meyers Squibb\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Medtronic. No fees are personally received. Corinna Miede is an employee of Mainanalytics ma GmbH, contracted by Boehringer Ingelheim International GmbH. Matias Nordaby is an employee of Boehringer Ingelheim International GmbH. Jonas Oldgren has received fees to his institution from AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, Portola, Roche Diagnostics, and Sanofi. Philippe Gabriel Steg has received research grants from Amarin, Bayer, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer\/Janssen, Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, and Servier. Jurri\u00ebn M. ten Berg has received advisory\/consulting\/speaker fees from Accumetrics, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lily, Ferrer, The Medicines Company, and Pfizer, and has received research grants from AstraZeneca, ZonMw. Lucas C. Godoy has no conflicts of interest that are directly relevant to the content of this article. Christopher P. Cannon has received research grants from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, and Pfizer and consulting fees from Aegerion, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, BGB, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee at each participating center and all procedures were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}